Evgen Pharma Plc (LON:EVG) CEO Dr Stephen Franklin talks to DirectorsTalk about its final results for the year ended 31 March 2017. Stephen reminds us of who Evgen Pharma are and what is in the development pipeline at the moment, talks us through the main result highlights and explains when the current clinical trials report, and what else can we expect in terms of news flow between now and then.
Evgen Pharma Plc is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The Company’s core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. The company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire and its registered office is at the Liverpool Science Park, Liverpool.